On April 7, 2026 in Boston, TransCode Therapeutics, Inc. (NASDAQ: RNAZ) disclosed a recent agreement with an institutional entity. The company, renowned for its advancements in immuno-oncology and RNA therapies targeting high-risk and advanced cancer, operates in the clinical stage. This deal marks a significant development for the firm as it continues to innovate in the field of cancer treatment.